多巴胺D_(2/3)受体和5-HT_(1A)受体部分激动剂卡利拉嗪的药理作用和临床评价

Pharmacological and clinical evaluation of cariprazine-dopamine D_(2/3) and 5-HT_(1A) receptor partial agonist in the treatment of schizophrenia and major depressive disorder

卡利拉嗪是一种新型的、多巴胺D_(2/3)受体和5-HT_(1A)受体部分激动剂,主要用于精神分裂症以及双相Ⅰ型情感障碍相关的躁狂急性发作或混合发作的治疗。本品最常见的不良反应为锥体外系症状,如静坐不能、颤动、呕吐和失眠等。本文对其药理作用、药动学、临床评价、安全性、用法用量和药物相互作用进行综述。

Cariprazine is a novel dopamine D3 and D2receptor partial agonist which is indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder. It is also a partial agonist at 5-HT1 Areceptor. The most common adverse events were extrapyramidal symptoms,for instance akathisia,tremor,vomiting and insomnia. The pharmacology,pharmacokinetics,clinical research,safety,dosage,and drug interactions were reviewed in this paper.